Investigating New Cancer Treatment Options
to Improve Patients’ Lives


Immune Design is developing first-in-class immuno-oncology drug candidates designed to make a meaningful difference for cancer patients. Below, please find a list of our current clinical trials.

Follicular Non-Hodgkin’s Lymphoma: G100

Title: Phase 1/2 Study of Intratumoral G100 Therapy in Patients with Follicular Non-Hodgkin’s Lymphoma

Objective: To evaluate the safety and tolerability of ascending doses of intratumoral G100 in patients with follicular non-Hodgkin’s lymphoma (NHL) receiving local radiation

Status: Active/Recruiting

More Information: identifier: NCT02501473